title: Extended protection against phlebovirus infection conferred by recombinant adenovirus expressing consensus interferon (DEF201).
abstract: Punta Toro virus (PTV; Bunyaviridae, Phlebovirus) is related to Rift Valley fever virus (RVFV), a pathogenic agent which causes severe disease in humans and livestock primarily in the sub-Saharan region of Africa. The recent range expansion of RVFV and the potential for its intentional release into naïve populations pose a significant threat to public health and agriculture. Studies modeling disease in rodents and nonhuman primates have shown that PTV and RVFV are highly sensitive to the antiviral effects of alpha interferon (IFN-α), an important component of the innate antiviral host response. While recombinant IFN-α has high therapeutic value, its utility for the treatment of neglected tropical diseases is hindered by its short in vivo half-life and costly production of longer-lasting pegylated IFNs. Here, we demonstrate extended preexposure protection against lethal PTV challenge following a single intranasal administration of DEF201, which is a replication-deficient human adenovirus type 5 vector engineered to constitutively express consensus IFN-α (cIFN-α) from transduced host cells. DEF201 was also efficacious when administered within 24 h as a postexposure countermeasure. Serum concentrations of cIFN-α could be detected as early as 8 h following treatment and persisted for more than 1 week. The prolonged antiphlebovirus prophylactic effect, low production costs, and ease of administration make DEF201 a promising agent for intervention during natural disease outbreaks and for countering possible bioterrorist acts.
authors.affiliation: Institute for Antiviral Research and Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, Utah, USA. brian.gowen@usu.edu
authors.forename: Brian B
authors.initials: BB
authors.lastname: Gowen
authors.forename: Jane
authors.initials: J
authors.lastname: Ennis
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Sefing
authors.forename: Min-Hui
authors.initials: MH
authors.lastname: Wong
authors.forename: Kie-Hoon
authors.initials: KH
authors.lastname: Jung
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Turner
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000281:Administration, Intranasal; D000818:Animals; D000998:Antiviral Agents / Q000097:blood / Q000378:metabolism; D002044:Bunyaviridae Infections / Q000517:prevention & control*; D006224:Cricetinae; D005260:Female; D005822:Genetic Vectors; D016898:Interferon-alpha / Q000097:blood / Q000235:genetics* / Q000378:metabolism*; D008099:Liver / Q000821:virology; D008647:Mesocricetus; D016856:Phlebovirus; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins